<p>Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy</p>-Reference-Cited by-同舟云学术

Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy

Published:2020-06 Issue: Volume:Volume 14 Page:2487-2501
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Mohan Viswanathan,Mithal Ambrish,Joshi Shashank R,Aravind SR^ORCID,Chowdhury Subhankar

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference56 articles.

1. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications

2. International Diabetes Federation. IDF diabetes atlas 9th edition; 2019. Available from: https://www.diabetesatlas.org/en/resources/.Accessed December 20, 2019.

3. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents

4. RE: Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2019 Executive Summary

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Remogliflozin in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis;Cureus;2024-08-04

2. Synthesis of Chirally Enriched Pyrazolylpyrimidinone-Based Glycohybrids via Annulation of Glycals with 2-Hydrazineylpyrimidin-4(3H)-ones;The Journal of Organic Chemistry;2024-03-12

3. Remogliflozin Etabonate (Re) the Latest Addition to the SGLT2 Inhibitor;Asian Journal of Pharmacy and Technology;2024-03-04

4. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop;Molecular Genetics and Metabolism;2024-03

5. Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD);Diabetes Obesity Metabolic Syndrome;2023-10-27